While the yield curve recently inverted, there are no clear sign of an imminent recession, notes sen...
Buy Dollar General for a slightly stronger than expected U.S. economy
11/01/2012 5:48 pm EST
I think Dollar General stands out from its competitors such as Dollar Tree (DLTR) because it 1) has moved to add groceries to its mix, making it a more attractive one-stop shopping destination, 2) added more brand names to its product offerings, and 3) isn’t just expanding (625 new stores in 2012) but relocating and renewing stores (575 in 2012) to upgrade the shopping experience.
That has enabled the company to grow gross margins to 31.7% in fiscal 2011 from 25.8% in 2006. And to grow same store sales at a 5.1% rate in the most recent quarter. The company projects same store sales growth of 5.2% for 2012.
Despite an existing store count of 9,800, Dollar General still has room for growth. The company only entered California this year with its first 50 stores. Dollar General operates 1,000 stores in Texas—matching that would give Dollar General plenty of growing room.
So far, growth in the second half of the company’s expansion—management talks about a goal of 20,000 stores--hasn’t resulted in a dip in sales per store. New store sales are actually 43% higher now than they were in 2007 and that has reduced the payback on invested capital per new store to 1.6 years from 2.2 years.
I’d put a target price on these shares of $57 by April 2013.
Full disclosure: I don’t own shares of any of the companies mentioned in this post in my personal portfolio. The mutual fund I manage, Jubak Global Equity Fund http://jubakfund.com/ , may or may not now own positions in any stock mentioned in this post. The fund did not own shares of Dollar General as of the end of June. For a full list of the stocks in the fund as of the end of June see the fund’s portfolio at http://jubakfund.com/about-the-fund/holdings/
Related Articles on STOCKS
Vanguard Energy Fund Investors Shares (VGENX) is a good choice for investors who want exposure to th...
Pacira Pharmaceuticals (PCRX) recently acquired MyoScience which markets the Iovera system, an FDA a...
Imagine a squadron of battle-ready drones flying alongside U.S. military fighter jets. It’s no...